Mertens LS, et al. - Long-term oncological outcome after cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal metastases (PM) of urachal adenocarcinoma (UrAC) were reported. Researchers analyzed 55 patients with UrAC treated at their hospital; CRS/HIPEC was undertaken in 10 patients who had PM; local treatment was undertaken in 35 with no metastases; palliative chemotherapy was provided to 10 with distant metastases. Outcomes revealed satisfactory long-term oncological outcome achievement with CRS/HIPEC in patients with PM of UrAC. For this group of patients, it could be a potentially curative treatment option.